PRESENTATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the MASH/NASH field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Presentations
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
No.13
AASLD 2012,
“Comparative proteomic analysis of the liver in a murine model of non- alcoholic steatohepatitis” Third Department of Internal Medicine, Niigata University Medical School
No.12
AASLD 2012,
“Inhibition of endoplasmic reticulum stress by 4-phenylbutyrate prevents steatohepatitis progression and tumorigenesis in NASH-HCC model mice” Department of Gastroenterology, Juntendo University School of Medicine
No.11
AASLD 2012,
“Galectin-3 targeting drugs inhibit multiple pathological pathways leading to improvement of non-alcoholic steatohepatitis (NASH)” Galectin Therapeutics Inc.
No.10
Cancer Science,
AASLD 2012, “Hepatic gene expression of the SPTLC3 subunit of serine palmitoyltransferase is associated with the development of liver cancer in a NASH mouse model” Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medicine and Dental Sciencesq
No.9
The 72th Scientific Sessions ADA,
2012, “Linagliptin is an Effective Therapeutic for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)” Boehringer Ingelheim GmbH & Co. KG
No.8
DDW 2012,
“A Novel Murine Model Recapitulates the Pathogenesis of Human Non-alcoholic steatohepatitis (NASH) and NASH-related Hepatocellular Carcinoma”
No.7
DDW 2012,
“Effects of Telmisartan on a Murine Model of Non-alcoholic Steatohepatitis (NASH) and NASH-related Hepatocellular Carcinoma”
No.6
DDW 2012,
“The Chemical Chaperon 4-Phenylbutyrate Inhibits Liver Fibrosis and Tumorigenesis in High-Fat Diet With N-acetyl-β-D-glucosaminedase Inhibitor-Induced NASH Model Mice”Department of Gastroenterology, Juntendo University School of Medicine
No.5
EASL The International Liver CongressTM 2012 – 47th Annual Meeting of the European Association for the Study of the Liver,
“FXR agonists prevent steatosis, hepatocyte death and progression of NASH towards HCC in a hypoinsulinaemic mouse model of progressive liver disease” Phenex Pharmaceuticals AG